Company news

Processa Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

August 2, 2022

Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022

Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

April 19, 2022

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

April 4, 2022

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update

March 29, 2022

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4: 30 p.m. EST

March 22, 2022

Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update

November 10, 2021

Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis

November 3, 2021

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5: 30 p.m. EST

October 25, 2021

Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis

October 11, 2021

Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update

August 11, 2021

Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5: 30 p.m. EST

August 5, 2021

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

August 3, 2021

Processa Pharmaceuticals enters into a licensing agreement with Ocuphire Pharma, Inc., for the development of RX-3117

June 16, 2021

Processa Set to Join Russell Microcap® Index

June 7, 2021

Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

May 19, 2021

Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update

May 12, 2021

Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update

March 24, 2021

Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5: 30 p.m. ET

March 21, 2021

Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

March 16, 2021

Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement

March 1, 2021

Processa Pharmaceuticals Announces $10.2 Million Strategic Financing

February 16, 2021

Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update

November 11, 2020

Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

November 4, 2020

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5: 30 p.m. ET

November 2, 2020

Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer

October 12, 2020

Processa Pharmaceuticals Closes $19.2 Million Public Offering

October 5, 2020

Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market

October 1, 2020

Processa Pharmaceuticals entered into a contingent precedent in-licensing agreement with Elion Oncology for the development of eniluracil (PCS6422) for the treatment of advanced gastrointestinal tumors

August 26, 2020

Processa Pharmaceuticals enters into a licensing agreement with Yuhan corporation for the development of YH12852 in functional gastrointestinal disorders

August 19, 2020

Processa Pharmaceuticals announces that it has entered into an agreement with Aposense, LTD to license in the next generation irinotecan drug

May 31, 2020

Processa Pharmaceuticals to move forward with a PCS499 Phase 3 trial after a successful FDA meeting

March 29, 2020

Processa Pharmaceuticals announces results from the Phase 2 study in necrobiosis lipoidica

March 16, 2020

Processa Pharmaceuticals announces formation of its medical and scientific advisory board

March 4, 2020

Processa Pharmaceuticals appoints Geraldine Pannu as an independent director to the board of directors

February 12, 2020

Processa Pharmaceuticals announces 1 for 7 reverse stock split of its common stock

December 19, 2019

Processa Pharmaceuticals provides an update on positive results from PCS-499 Phase 2 trial

December 3, 2019

← Newer news releases

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 39 decks. Every deck is listed under its year.